---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-125505"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T09:14:09.990905+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma CMO Mina Pastagia departs; separation agreement provides 12-month salary continuation

## Summary
- Dr. Mina Pastagia terminated as Chief Medical Officer effective Nov 13, 2024; separation agreement executed Dec 2, 2024.
- Agreement provides 12 months of base salary continuation, paid in equal installments starting ~60 days post-termination.
- All unvested stock options and restricted stock units forfeited; vested options must be exercised within 90 days of separation.
- Pastagia releases all claims against the company in exchange for the severance benefits.

## SEC filing metadata
- accession: 0001104659-24-125505
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465924125505/0001104659-24-125505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465924125505/tm2430081d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-125505
- JSON: https://secwatch.observer/filing/0001104659-24-125505.json
- Plain text: https://secwatch.observer/filing/0001104659-24-125505.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.